Bridgebio Pharma Inc (BBIO) valuation history
$68.56
Latest weekly close · Market cap $13.4B
Share BBIO EV/Sales history
Below its usual range
As of
BBIO's EV/Sales of 21.5x is lower than 76% of its weekly readings since August 2022.
Weekly EV/Sales since August 2022
EV/Sales each weekMiddle half of its readingsMedian 26.5×
- Median
- 26.5×
- Low to high
- 6.0×–67.5×
- Versus median
- -19%
- History starts
- August 2022
EV/Sales
24thpercentile
of its weekly readings since August 2022
Below its usual range
Growth, last 12 months vs the year before
- Revenue
- +202%accelerating
- EPS
- n/a
Price vs revenue and EPS, indexed to 100
Each line starts at 100 at its first positive reading over the last five years. Revenue and EPS change at fiscal quarter ends. EPS was not positive in this window, so it is left out.
PriceRevenue, last 12 months100 = first reading
EV/Sales at each year-end
The last weekly reading of each year, and its percentile against the five years before it.
| Year-end | EV/Sales | 5-year percentile |
|---|---|---|
| 46.3× | 90 | |
| 25.1× | 73 | |
| n/a | Too little history | |
| 6.4× | Too little history |
Loading peers and related research…
About this history
- What is BBIO's current EV/Sales?
- BBIO's EV/Sales of 21.5x is lower than 76% of its weekly readings since August 2022.
- What is BBIO's five-year median EV/Sales?
- 26.5x. Half of BBIO's weekly readings since August 2022 were higher and half were lower. This page has 221 weekly readings, from Aug 1, 2022 to Oct 19, 2026.
- Does a low historical rank mean a stock is a buy?
- No. The rank compares BBIO only with its own past. Slower growth or more risk can justify a lower multiple than before. P/E uses earnings and P/S uses revenue from the last twelve months.